3-bromo-6-chloro-1-indanone | 80272-44-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 茚满类
• 英文名称: 3-bromo-6-chloro-1-indanone
• 英文别名: 3-bromo-6-chloroindan-1-one；3-bromo-6-chloro-2,3-dihydroinden-1-one
• CAS: 80272-44-2
• 化学式: C₉H₆BrClO
• 分子量: 245.503
• InChiKey: ITVBGLYRLIPIAG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  12
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  17.1
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  3-bromo-6-chloro-1-indanone 在 三乙胺 作用下， 以 四氢呋喃 为溶剂， 反应 8.0h， 生成 6-chloroinden-1-one
  参考文献：
  名称：

  DEUTERATED 1-PIPERAZINO-3-PHENYL-INDANES FOR TREATMENT OF SCHIZOPHRENIA

  摘要：

  本发明涉及氘代1-哌嗪基-3-苯基茚烷及其盐，具有在中枢神经系统中对多巴胺受体D1和D2以及5HT2受体的活性，涉及包含这些化合物作为活性成分的药物、将这些化合物用于治疗中枢神经系统疾病的用途，以及包括给予这些化合物的治疗方法。

  公开号：

  US20120322811A1

文献信息

• Indane derivatives, pharmaceutical compositions thereof and method of
  申请人：Kefalas A/S

  公开号：US04443448A1

  公开（公告）日：1984-04-17

  The present invention relates to novel 1-piperazino-3-phenyl-indane derivatives which have pronounced psychopharmacological activity such as neuroleptic activity, analgesic activity, antidepressant activity and, at the same time, a low degree of undesired side-effects, methods for the preparation of said indane derivatives, pharmaceutical compositions containing same, and methods for the treatment of psychic disorders, such as psychoses and depressions and pain, by administering a therapeutically active amount of one of said derivatives to a living animal body, including human beings.

  本发明涉及一种新型的1-哌嗪-3-苯基-茚衍生物，其具有显著的心理药理活性，如神经阻滞活性、镇痛活性、抗抑郁活性，同时具有低程度的不良副作用，制备该茚衍生物的方法，含有该茚衍生物的制药组合物，以及通过向生物体，包括人类，施加所述衍生物之一的治疗有效量来治疗心理障碍，如精神病和抑郁症和疼痛的方法。
• DEUTERATED 1-PIPERAZINO-3-PHENYL INDANES FOR TREATMENT OF SCHIZOPHRENIA
  申请人：H. LUNDBECK A/S

  公开号：US20130281436A1

  公开（公告）日：2013-10-24

  The present invention relates to deuterated 1-piperazino-3-phenyl-indanes and salts thereof with activity at dopamine receptors D 1 and D 2 as well as the 5HT 2 receptors in the central nervous system, to medicaments comprising such compounds as active ingredients, to the use of such compounds in the treatment of diseases in the central nervous system, and to methods of treatment comprising administration of such compounds.

  本发明涉及氘代1-哌嗪基-3-苯基-茚烷及其盐，其在中枢神经系统中具有对多巴胺受体D1和D2以及5HT2受体的活性，以及包含此类化合物作为活性成分的药物、使用此类化合物治疗中枢神经系统疾病的方法和包括给予此类化合物的治疗方法。
• Deuterated 1-piperazino-3-phenyl-indanes for treatment of schizophrenia
  申请人：Jorgensen Morten

  公开号：US08575174B2

  公开（公告）日：2013-11-05

  The present invention relates to deuterated 1-piperazino-3-phenyl-indanes and salts thereof with activity at dopamine receptors D1 and D2 as well as the 5HT2 receptors in the central nervous system, to medicaments comprising such compounds as active ingredients, to the use of such compounds in the treatment of diseases in the central nervous system, and to methods of treatment comprising administration of such compounds.

  本发明涉及氘代的1-哌嗪-3-苯基-茚烷及其在中枢神经系统中对多巴胺受体D1和D2以及5HT2受体具有活性的盐，以及包含此类化合物作为活性成分的药物、在中枢神经系统疾病治疗中使用此类化合物的方法以及包括给予此类化合物的治疗方法。
• Deuterated 1-piperazino-3-phenyl indanes for treatment of schizophrenia
  申请人：H. Lundbeck A/S

  公开号：US09012453B2

  公开（公告）日：2015-04-21

  The present invention relates to deuterated 1-piperazino-3-phenyl-indanes and salts thereof with activity at dopamine receptors D1 and D2 as well as the 5HT2 receptors in the central nervous system, to medicaments comprising such compounds as active ingredients, to the use of such compounds in the treatment of diseases in the central nervous system, and to methods of treatment comprising administration of such compounds.

  本发明涉及氘代的1-哌嗪基-3-苯基-茚烷及其盐，在中枢神经系统中对多巴胺受体D1和D2以及5HT2受体具有活性，以及包含这种化合物作为活性成分的药物、使用这种化合物治疗中枢神经系统疾病的方法以及包括给予这种化合物的治疗方法。
• Indane derivatives, methods of their preparation and compositions containing them
  申请人：KEFALAS A/S

  公开号：EP0035363A1

  公开（公告）日：1981-09-09

  1-Piperazino-3-phenylindane derivatives of the formula: wherein R1, R2, R3 and R4 are as defined in Claim 1, and their pharmaceutically acceptable acid addition salts. The compounds are prepared by the usual methods for analogous compounds. They have been found to have psychopharmacological and analgetic activity. Pharmaceutical compositions containing the compounds have been disclosed.

  式中 R1、R2、R3 和 R4 如权利要求 1 所定义的 1-哌嗪基-3-苯基茚满衍生物及其药学上可接受的酸加成盐。 这些化合物是用类似化合物的常规方法制备的。 它们具有精神药理学和镇痛活性。 含有这些化合物的药物组合物已被公开。